GnRH-a延长给药间隔治疗子宫内膜异位症的评价  

Evaluation of Lengthening the Time of GnRH-a Administration in the Treatment of Endometriosis

作　　者：江小香[1] 

机构地区：[1]福建省妇幼保健院妇产科,福建福州350001

出　　处：《中国卫生标准管理》2017年第27期84-86,共3页China Health Standard Management

摘　　要：目的评价促性腺激素释放激素激动剂(Gn RH-a)延长给药间隔治疗子宫内膜异位症的疗效。方法采用系统评价方法,检索EMBASE、Current Controlled Trials、MEDLINE、Clinical Trials、CENTRAL、CBM、CNKI、VIP、The National Research Registe等电子资料库至2015年3月。采用Cochran系统评价软件Rev Man5.0对收集的相关随机对照试验(RCTs)同质研究资料进行Meta分析。结果根据所纳入的5篇文献,Gn RH-a延长给药时间治疗子宫腺肌病和子宫内膜异位症与常规剂量疗效相似,差异无统计学意义(P>0.05),用药12周、24周延长给药间隔组雌激素水平高于常规剂量组,差异有统计学意义(P<0.05)。结论 Gn RH-a延长给药时间治疗子宫腺肌病与和子宫内膜异位症与常规剂量组疗效相似,降低了医疗费用,增加患者依从性。Objective To evaluate the effect of extended-interval dosing regimen of gonadotropin releasing hormone agonist （GnRH-a） in the treatment of adenomyosis and endometriosis. Methods EMBASE, Current Controlled Trials, MEDLINE, Clinical Trials, CENTRAL, CBM, CNKI, VIP, The National Research Registe and other electronic databases were retrieved in March 2015. Using the Cochran system evaluation software RevMan5.0, a meta-analysis was carried out on the collected data of the related randomized controlled trials （RCTs）. Results According to the included 5 articles, GnRH-a prolong drug treatment of uterine adenomyosis and endometriosis was similar to conventional dose effect, there was no statistically significant difference （P 〉 0.05）. The estrogen level in the interval group was higher than that in the routine dose group for 12 weeks and 24 weeks. The difference was statistically significant（P 〈 0.05）. Conclusion The use of extended-interval dosing regimen of triptorelin depot in adenomyosis and endometriosis result, which is similar to that achieved by conventional regimen. The new regimen significantly reduces the cost of treatment, increase patient compliance.

关 键 词：促性腺激素释放激素激动剂 子宫内膜异位症 延长给药间隔时间 

分 类 号：R711[医药卫生—妇产科学]